Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Cancer Immunol Res. 2015 May 26;3(10):1148–1157. doi: 10.1158/2326-6066.CIR-15-0059

Figure 5.

Figure 5

Healthy donors with the FcγRIIIa-158 V/V genotype display higher lysis of tumor cells than donors with the F/F genotype. Twenty healthy donors were genotyped for FcγRIIIa-158 polymorphism. An ADCC assay using the H441 human lung cancer cell line as a target was performed with purified NK cells from 3 donors with the V/V genotype and 3 donors with the F/F genotype. Avelumab was used at 0.5 ng/mL, and results are shown at E:T ratios of 12.5:1 and 6.25:1. Data shown are the mean±SD for each group. Results were analyzed using a parametric unpaired t test, p=0.026.